Sentences with phrase «unfavorable impact»

Redditors have voiced their frustration that the slew of issues associated with Bitcoin Gold — and other recent hard forks from the original Bitcoin blockchain — could potentially have an unfavorable impact on the entire cryptocurrency market.

Not making payments has a very unfavorable impact on your credit score.

The company blamed this loss on an «unfavorable impact from year - over-year changes in foreign exchange rates.»

Excluding the $ 178 million unfavorable impact from year - over-year changes in foreign exchange rates throughout the quarter, net sales grew 23 % compared with fourth quarter 2011.

The unfavorable impact from year - over-year changes in foreign exchange rates throughout the year on operating income was $ 14 million.

Excluding the $ 854 million unfavorable impact from year - over-year changes in foreign exchange rates throughout the year, net sales grew 29 % compared with 2011.

The unfavorable impact from year - over-year changes in foreign exchange rates throughout the year on net sales was $ 86 million.

Excluding the unfavorable impact from year - over-year changes in foreign exchange rates throughout the quarter, sales grew 28 %.

«Each of these effects might have unfavorable impact on cardiovascular mortality,» Dr. Staessen says.

This net tax benefit includes the estimated impact of the revaluation of U.S. net deferred tax liabilities based on the new lower corporate income tax rate, partly offset by the unfavorable impact of a repatriation tax.

Then there was $ 14 million in «unfavorable impact» attributable to tax items related to the separation from MetLife, Brighthouse said.

Not exact matches

Revenue for 2018 is expected to be approximately $ 25 million, which includes an approximately $ 1.1 million unfavorable revenue impact due to the adoption of the new revenue recognition standard (ASC Topic 606) in 2018, as well as the loss of a large customer in the fourth quarter 2017, representing revenue of approximately $ 3.2 million annually.

According to a recent Gallup poll, as many as seven in 10 women have an unfavorable opinion of Trump, and experts say his presidency could have a serious, negative impact on women's rights.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Such risks and uncertainties include, but are not limited to: our ability to achieve our financial, strategic and operational plans or initiatives; our ability to predict and manage medical costs and price effectively and develop and maintain good relationships with physicians, hospitals and other health care providers; the impact of modifications to our operations and processes; our ability to identify potential strategic acquisitions or transactions and realize the expected benefits of such transactions, including with respect to the Merger; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; the outcome of litigation, regulatory audits, investigations, actions and / or guaranty fund assessments; uncertainties surrounding participation in government - sponsored programs such as Medicare; the effectiveness and security of our information technology and other business systems; unfavorable industry, economic or political conditions, including foreign currency movements; acts of war, terrorism, natural disasters or pandemics; our ability to obtain shareholder or regulatory approvals required for the Merger or the requirement to accept conditions that could reduce the anticipated benefits of the Merger as a condition to obtaining regulatory approvals; a longer time than anticipated to consummate the proposed Merger; problems regarding the successful integration of the businesses of Express Scripts and Cigna; unexpected costs regarding the proposed Merger; diversion of management's attention from ongoing business operations and opportunities during the pendency of the Merger; potential litigation associated with the proposed Merger; the ability to retain key personnel; the availability of financing, including relating to the proposed Merger; effects on the businesses as a result of uncertainty surrounding the proposed Merger; as well as more specific risks and uncertainties discussed in our most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.cigna.com as well as on Express Scripts» most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.express-scripts.com.

Our international sales are primarily denominated in foreign currencies and any unfavorable movement in the exchange rate between U.S. dollars and the currencies in which we conduct sales in foreign countries could have an adverse impact on our revenue.

Rest of World net sales were $ 851 million, increasing 1.6 percent versus the year - ago period, despite an unfavorable currency impact of 1.4 percentage points.

These risks and uncertainties include food safety and food - borne illness concerns; litigation; unfavorable publicity; federal, state and local regulation of our business including health care reform, labor and insurance costs; technology failures; failure to execute a business continuity plan following a disaster; health concerns including virus outbreaks; the intensely competitive nature of the restaurant industry; factors impacting our ability to drive sales growth; the impact of indebtedness we incurred in the RARE acquisition; our plans to expand our newer brands like Bahama Breeze and Seasons 52; our ability to successfully integrate Eddie V's restaurant operations; a lack of suitable new restaurant locations; higher - than - anticipated costs to open, close or remodel restaurants; increased advertising and marketing costs; a failure to develop and recruit effective leaders; the price and availability of key food products and utilities; shortages or interruptions in the delivery of food and other products; volatility in the market value of derivatives; general macroeconomic factors, including unemployment and interest rates; disruptions in the financial markets; risk of doing business with franchisees and vendors in foreign markets; failure to protect our service marks or other intellectual property; a possible impairment in the carrying value of our goodwill or other intangible assets; a failure of our internal controls over financial reporting or changes in accounting standards; and other factors and uncertainties discussed from time to time in reports filed by Darden with the Securities and Exchange Commission.

Volume / mix was 0.7 percentage points lower as strong growth in condiments and sauces was more than offset by a combination of significantly lower shipments in India, unfavorable holiday - related shipment phasing in Indonesia, as well as the impact of distributor network realignment in several markets.

Adjusted EBITDA increased 0.7 percent versus the year - ago period to $ 2.1 billion, despite an unfavorable 1.2 percentage point impact from currency.

Net sales were $ 6.7 billion, down 1.7 percent versus the year - ago period, including an unfavorable 0.8 percentage point impact from currency.

Canada Segment Adjusted EBITDA decreased 1.2 percent versus the year - ago period to $ 189 million, including an unfavorable 3.5 percentage point impact from currency.

Rest of World Segment Adjusted EBITDA decreased 11.6 percent versus the year - ago period to $ 180 million, including an unfavorable 3.0 percentage point impact from currency.

Comprehensive loss to shareholders and book value per share were impacted by declines in both our fixed income and equity portfolios, driven by an increase in interest rates and unfavorable movements in the equity markets during the period.

Unions are also pushing for a legislative response that might mute the impact of an unfavorable Janus decision.

3) to discredit the news organizations as a way to minimize the impact of stories unfavorable to the administration: nobody is going to take fake news seriously.

Participants were asked to rate their health from poor to excellent and complete the Financial Strain Questionnaire which captures how an unfavorable income may impact lifestyle like suitable food, housing and clothing.

Those with doubts about the viability of the movie Entourage had them confirmed when the film drew unfavorable reviews and made little impact at the box office, where it opened as counterprogramming in June against summer's typically big - budgeted fare.

Risks and uncertainties include without limitation the effect of competitive and economic factors, and the Company's reaction to those factors, on consumer and business buying decisions with respect to the Company's products; continued competitive pressures in the marketplace; the ability of the Company to deliver to the marketplace and stimulate customer demand for new programs, products, and technological innovations on a timely basis; the effect that product introductions and transitions, changes in product pricing or mix, and / or increases in component costs could have on the Company's gross margin; the inventory risk associated with the Company's need to order or commit to order product components in advance of customer orders; the continued availability on acceptable terms, or at all, of certain components and services essential to the Company's business currently obtained by the Company from sole or limited sources; the effect that the Company's dependency on manufacturing and logistics services provided by third parties may have on the quality, quantity or cost of products manufactured or services rendered; risks associated with the Company's international operations; the Company's reliance on third - party intellectual property and digital content; the potential impact of a finding that the Company has infringed on the intellectual property rights of others; the Company's dependency on the performance of distributors, carriers and other resellers of the Company's products; the effect that product and service quality problems could have on the Company's sales and operating profits; the continued service and availability of key executives and employees; war, terrorism, public health issues, natural disasters, and other circumstances that could disrupt supply, delivery, or demand of products; and unfavorable results of other legal proceedings.

Similar one - off events that could impact the company's near - term earnings (but would probably be buying opportunities) include a mine failure, accident, or unfavorable regulation that temporarily halts production.

The investment manager expects to hold an unhedged, fully - invested position in common stocks in environments where the expected return from market risk is believed to be high, and may reduce or «hedge» the exposure of the Fund's stock portfolio to the impact of general market fluctuations in environments where the expected return from market risk is believed to be unfavorable.

The investment manager expects to intentionally «leverage» or increase the stock market exposure of the Fund in environments where the expected return from market risk is believed to be high, and may reduce or «hedge» the exposure of the Fund's stock portfolio to the impact of general market fluctuations in environments where the expected return from market risk is believed to be unfavorable.

When market conditions are unfavorable in the view of Hussman Strategic Advisors, Inc., the Fund's investment manager, the Fund may use swaps, index options and index futures, or effect short sales of exchange traded funds («ETFs»), to reduce the exposure of the Fund's stock portfolio to the impact of general market fluctuations or to market fluctuations within a specific country or geographic region.

This can have the effect of steering homeowners into unfavorable mortgages based on where they live, which has a disparate impact on communities of color.

It appears that Pruitt instructed the EPA career staff to make assumptions grossly unfavorable to the CPP in order to calculate the largest possible negative economic impact; for example, the RIA models scenarios that minimize the CPP's reductions in unhealthy air pollutants, inflate the costs of compliance, only count the climate benefits of CO2 reductions in the US, and greatly discount the future benefits of lower global temperatures.

We have successfully employed what we call media - mitigation tactics to minimize the potential for negative impact associated with unfavorable news coverage.

When it comes to writing your resume, we have several strategies for minimizing the impact of unfavorable date gaps within the resume.

EIP showed favorable impacts on 8 outcomes, including fewer days and episodes of hospitalization, relative to those in the comparison group, covering a range of 6 weeks to 2 years postpartum.13, 23,24 EIP also showed a favorable effect on the percentage of children who were adequately immunized by 1 year, but the difference was no longer statistically significant by 2 years.13, 24 Early Start demonstrated favorable effects on 3 outcomes, including percentage who received well - child visits and dental service.25 — 27 HFA had favorable results for 4 health care outcomes, such as the number of well - child visits and whether the child had health insurance.28 — 31 HFA had an unfavorable effect on the number of pediatric emergency department (ED) visits.32 The research showed that Healthy Steps had a beneficial effect on 2 outcomes: 1 - month well - child visits and diphtheria toxoid, tetanus toxoid, and pertussis vaccinations.33 Finally, NFP had favorable results on 3 outcomes measuring the number of ED visits at different follow - ups but an unfavorable / ambiguous effect on number of days hospitalized between 25 and 50 months.34, 35 The research on 2 programs (Oklahoma's CBFRS and PAT) showed no effects on measures of health care use or coverage.36 — 40 The research on 5 programs (Child FIRST, EHS, Family Check - Up, HIPPY, and PALS for Infants) did not report health care coverage or usage outcomes.